Is Wegovy Safe During Pregnancy — and What Should You Do If You Conceive on It?

Why regulators say Wegovy is not suitable in pregnancy

The guidance on semaglutide and pregnancy does not come from a gap in evidence so much as from the nature of the evidence that exists. Pregnant women were excluded from the STEP clinical trials (the programme that underpins Wegovy's licence) which is standard practice for phase 3 drug studies. What researchers do have are animal studies, and those studies are concerning: in rodents and rabbits, semaglutide at doses proportionate to those used clinically was associated with foetal growth restriction, structural abnormalities and pregnancy loss. That data, combined with the absence of human safety data, is why the UK's NHS patient guidance on semaglutide and the medicine's Summary of Product Characteristics both state clearly that it should not be used during pregnancy.

There is a misconception worth addressing here: some people assume that because Wegovy works on hormones the body already produces, it must be safe at all stages of life. GLP-1 receptors are present in multiple tissues, including those involved in foetal development, and the effect of a pharmacological agonist on those receptors during pregnancy is not established as benign. That assumption, however understandable, is not supported by the available science, and our page on whether semaglutide is safe in pregnancy sets out the full clinical reasoning behind that position.

The practical upshot: if you are pregnant, planning to become pregnant, or breastfeeding, Wegovy is not appropriate. This is not a grey area in current UK guidance.

What the wash-out guidance means and how contraception fits in

The MHRA advises that women use effective contraception while on GLP-1 receptor agonist medicines and for a defined period before attempting to conceive. The specific wash-out timing for semaglutide should be confirmed with your prescriber, as it accounts for the medicine's half-life and elimination from the body. It is not simply a matter of stopping the pen and waiting a week.

A separate, related point applies to anyone on Wegovy who also takes the oral contraceptive pill. The NHS England weight-management injections guidance notes that for tirzepatide specifically, gastric slowing may reduce pill absorption, requiring an additional barrier method. For semaglutide, current evidence does not indicate the same level of risk to oral contraceptive absorption, but this is worth raising with your GP if you rely on the pill. The broader point stands: contraception planning and GLP-1 treatment overlap more than many people expect, and a clinician should be part of that conversation.

If you became pregnant unexpectedly while on Wegovy, the guidance is to stop the medicine and contact your GP or midwife the same day. Document the date of your last dose so your maternity team has an accurate picture, and our guide to Wegovy side effects in pregnancy explains what to discuss with your maternity team at that first conversation.

What stopping Wegovy during pregnancy means for weight management

Stopping semaglutide when pregnant raises a legitimate question: what happens to weight, and does discontinuing treatment carry its own risks? The honest answer is that this requires individual clinical assessment. Some weight regain is common after stopping GLP-1 treatment (the STEP 1 trial data and subsequent extension studies both documented this pattern) but the risks of continuing semaglutide in pregnancy are not comparable to the risks of short-term weight regain, particularly under the supervision of a maternity team.

Pregnancy is not the moment for unsupported weight-loss treatment. It is the moment for obstetric care, and any concerns about metabolic health during pregnancy belong with a midwife, obstetrician or GP. If you had weight-related conditions before conception, those should be disclosed to your maternity team so they can be monitored through the pregnancy, and our detailed page on whether Wegovy is safe during pregnancy covers the evidence that informs that clinical picture. Resuming weight-management treatment after birth (and after breastfeeding, if applicable) is a conversation worth having with a prescriber at the right time.

For a broader picture of Wegovy's side-effect profile outside of pregnancy, our detailed guide covers what the clinical trials reported and how most people's experience differs from the headline numbers.

Getting support and what to do next

If you have questions about stopping Wegovy, the timing of contraception, or resuming treatment after a pregnancy, those are exactly the questions our prescribers handle. Every consultation at nume is personally reviewed by a GPhC-registered Independent Prescriber on the same day, a real clinician reading your answers, not a software queue. You can also read about how our clinical team approaches complex situations.

If you are currently pregnant, the right route is your GP or midwife, not an online pharmacy consultation. We can support you with weight-management treatment at the appropriate time after your pregnancy, when a prescriber can make a full clinical assessment. Take a look at our treatment options when the time is right, or read our FAQs for general questions about how the service works.

For more on the evidence around semaglutide's pregnancy risk in clinical terms, or practical detail on stopping Wegovy safely, those pages cover the specifics in full.